Liraglutide
FDA ApprovedAn FDA-approved GLP-1 receptor agonist. Developed by Novo Nordisk for type 2 diabetes, also approved for chronic weight management under the brand name Saxenda.
Weight ManagementMetabolic HealthGLP-1 Agonist
Half Life
~13 hours
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyDaily
Cost$$$
🐾 Griffin Says...
The predecessor to semaglutide in the GLP-1 family. Daily injection vs weekly for sema, which is a consideration. The SCALE trial showed participants lost an average of 18.5 lbs over 56 weeks. Solid data.
Benefits
- Weight reduction
- Blood sugar control
- Appetite suppression
- Cardiovascular benefits
- Kidney protection research
Best For
- Weight management research
- Type 2 diabetes research
- Metabolic health
Body Systems
MetabolicCardiovascularEndocrine
Mechanisms of Action
- GLP-1 receptor agonist
- Slows gastric emptying
- Reduces appetite
- Increases insulin secretion
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very Common | Mild-Moderate |
| Vomiting | Common | Mild |
| Diarrhea | Common | Mild |
Contraindications
Thyroid cancer history, pancreatitis, pregnancy
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator